Angitia’s latest megaround to fuel mid-stage milestones: Venture Report

Musculoskeletal company Angitia has raised another nine-digit round, adding $130 million in fresh series D cash just 14 months after its $120 million series C. The biotech had also raised $156 million in its series B across multiple installments in 2021-24; it has now drawn $454 million to date.

Frazier Life Sciences and Venrock Healthcare Capital Partners came in as new investors in Angitia Biopharmaceuticals Ltd., which has three clinical programs for osteoporosis, osteogenesis imperfecta and spinal fusion. A company spokesperson told BioCentury the first two biologics, both in Phase II testing, are Angitia’s lead programs; the spinal fusion program is in a Phase III study that has not yet delivered data...